Introduction {#Sec1}
============

The efficacy of 5-fluorouracil (5FU)-based adjuvant chemotherapy and the associated survival benefit have been firmly established for patients with stage III colorectal cancer (CRC) \[[@CR1]\]. However, the use of adjuvant therapy for stage II colon cancer patients remains controversial \[[@CR2]\]. Typically, only high-risk stage II CRCs are treated. Hence, there is a need for predictive factors to support treatment decisions in this group of patients, the majority of whom will be cured by surgery alone \[[@CR3]\]. This is especially important because a wider implementation of prophylactic programs in recent years has resulted in an increased number of patients with stage B2 tumors.

5-Fluorouracil has been used to treat colorectal cancer patients for a long time \[[@CR4]\]. The target enzyme for 5FU is thymidylate synthase (TS). This enzyme catalyzes the conversion of deoxyuridine-5′monophosphate to deoxythymidine-5′-monophosphate and is therefore essential for DNA synthesis and repair. Resistance to 5FU-based treatment might depend both on the level of expression of TS and other enzymes involved in the metabolism of 5FU and on mechanisms involved in cell growth or apoptosis. p21^WAF1^ is a multifunctional cell cycle-related protein that inhibits cyclin-dependent kinases (CDKs), which results in cell cycle arrest in the G1 phase \[[@CR5]\]. p21^WAF1^ expression is known to be inversely related to cell proliferation and directly related to terminal differentiation \[[@CR6]\]. Recently, it has been shown that TS expression was upregulated in p21^WAF1^-/- human colorectal cancer HCT116 cells, and TS promoter activity was downregulated by ectopic p21 expression \[[@CR7]\]. Furthermore, a CDK inhibitor reduced expression of TS in a dose-dependent manner, and the reduction resulted in enhancement of sensitivity to 5FU in cultured human colon cancer cells \[[@CR8]\]. Taken together with other reports \[[@CR9]\], this suggests a great importance of p21^WAF1^ for in vitro response to chemotherapeutic agents and that the CDK inhibitor p21^WAF1^ regulates thymineless stress-induced DNA damage. Hence, p21^WAF1^ expression might have a predictive significance in 5FU-treated CRC patients. In several \[[@CR10]--[@CR19]\] but not all \[[@CR20]--[@CR24]\] previous studies, positive p21^WAF1^ expression has been suggested as an indicator of good prognosis in patients with stage III/IV CRC. However, it is not known whether the same is true for stage B2 patients. Therefore, our purpose was to assess the influence of p21^WAF1^ expression on disease-free survival (DFS) and overall survival (OS) of Astler--Coller stage B2 patients with CRC who either were or were not treated with 5FU-based adjuvant chemotherapy, and of stage C patients treated with adjuvant chemotherapy.

Materials and methods {#Sec2}
=====================

**Patients** This retrospective study was based on tumor tissue from 275 unselected patients who underwent potentially curative colorectal resection for sporadic CRC (defined as an absence of relevant family history at the time of admission to the hospital). Distant metastases at the time of operation were excluded by preoperative liver ultrasonography, chest x-ray, and intraoperative exploration. Table [1](#Tab1){ref-type="table"} lists the clinico-pathological details of the 275 tumors and patients. Astler--Coller staging of CRC based on the extent of local invasion and the status of lymph nodes was used \[[@CR25]\]. In this system, stage B2 denotes the tumor penetrating through the muscularis propria and uninvolved nodes, stage C---tumors extending into the muscularis propria or penetrating through it with lymph node metastases. The mean age of the patients was 61.1 ± 10.8 years (range, 33--83; median, 62). The splenic flexure was regarded as the border between the proximal and distal colon. The Research Ethics Committee of Pomeranian Medical University approved this study. Table 1Relations between p21^WAF1^ expression and clinico-pathological parametersParameterp21^WAF1^ Expression*nn* (%)*p*Age (years)\<6213887 (63)0.39\>6213779 (58)Sex Females12075 (63)0.54 Males15591 (59)GradeG1 + G215691 (58)0.46G3^a^11975 (63)Astler--CollerB213372 (54)*0.049*C14294 (66)SiteProximal5337 (70)0.16Distal222129 (58)SiteRectum13881 (59)0.62Colon13785 (62)Radiotherapy (rectal tumors)Preoperative4326 (61)0.85Postoperative RT and no RT^b^9353 (57)^a^Including mucinous carcinoma^b^Radiotherapy status unknown in two casesTumors were resected between July 1997 and April 2004 in the Departments of Surgery of the teaching hospitals of Pomeranian Medical University in Szczecin and the Regional Oncological Center in Szczecin, Poland. The operations consisted of either a resection with lymphadenectomy or a total mesorectal excision for rectal carcinomas. A total of 203 (74%) patients (83 high-risk stage B2 and 120 stage C) were treated with adjuvant chemotherapy (six 5-day courses of bolus infusion of 5FU (425 mg/m^2^) every 4 weeks combined with leucovorin, 20 mg/m^2^). A total of 72 patients (22 stage C patients) did not receive adjuvant chemotherapy due to internist contraindications.A total of 41 patients with rectal cancer received postoperative radiotherapy (50.4 Gy), and 43 patients, preoperative radiotherapy (5 × 5 Gy). Of the 133 Astler--Coller stage B2 tumors, there were 65 rectal tumors, and of these, 24 (18%) received preoperative and 11 (8.3%) received postoperative radiotherapy. Radiotherapy did not influence DFS (*p* = 0.61) nor OS (*p* = 0.83) of patients with rectal tumors. Since we did not find a statistically significant difference in p21^WAF1^ expression between the group of patients subjected to preoperative radiotherapy and the remaining 93 rectal tumors not treated with preoperative radiotherapy (Table [1](#Tab1){ref-type="table"}), the former was included in the study.Time from the surgery until the time of death due to cancer or to last known follow-up was regarded as OS, and the time until the first appearance of metastasis or local recurrence was regarded as DFS. The median follow-up was 54 months (mean, 57.3 ± 30.5 months; range, 5--143 months). During the follow-up, 66 of the 275 (24%) patients died of their disease, and 165 (60%) were alive without symptoms from the disease. Recurrences were found in 106 patients. Four patients died of non-cancer-related causes, and they were treated as censored observations.

**Tissue microarray (TMA) construction** Tumor areas with the highest mitotic activity at the outer invasive zone of the cancer were chosen for tissue microarrays which were constructed as previously described \[[@CR26]\].

**Immunohistochemistry** Slides with tissue microarrays were deparaffinized, rehydrated, and had the endogenous peroxidase activity blocked. Slides were immersed in pH 9.0 buffer, and heat-induced antigen retrieval was performed in a pressure cooker (Pascal, Dako, Glostrup, Denmark). Monoclonal p21^WAF1^ antibody (Dako) was used (dilution, 1:25; incubation time, 30 min), and the slides were immunostained using a Dako EnVision+ kit according to the manufacturer's instructions. We used the sensitive EnVision+ visualization system because the detection system used is regarded as a critically important variable in immunohistochemical analysis, and detection methods using signal amplification with HRP-labeled polymers have been shown to be more sensitive than methods without such a layer of amplification \[[@CR27]\]. The reaction was developed with diaminobenzidine substrate--chromogen solution, and the slides were counterstained with hematoxylin. Positive controls included colorectal adenocarcinoma previously shown to have a high level of p21^WAF1^ expression. Negative controls omitted the primary antibody. The immunohistochemical procedure for all tissue microarrays from 275 tumors was performed at the same time in identical conditions because, instead of 275 histological slides of whole tissue sections, only four slides containing tissue cores from all 275 tumors were processed.

**Scoring** Immunohistochemical staining for each tumor core was independently assessed by two observers (PD and WD) who were blinded to the clinical and pathological data. In cases of disagreement, the result was reached by consensus. The percentage of tumor cell nuclei with unequivocal staining was recorded for each core. P21^WAF1^ expression in tumors was variable, and so, tumors were classified as negative (\<1% of positive tumor cells) or positive (if ≥1% of tumor cells showed nuclear immunoreactivity).

**Statistical analysis** Associations between the presence of p21^WAF1^ expression in tumors and other categorical variables were analyzed with the Fisher exact test. The Kaplan--Meier method was used for the univariate survival analysis, and the differences between compared groups were assessed by the log-rank test. A Cox proportional hazards model was used for univariate and multivariate analyses of factors associated with OS and DFS. The independent variables included in the model were: age, gender, tumor site, Astler--Coller stage, histological grade, 5FU-based adjuvant chemotherapy, and presence of p21^WAF1^ expression. A *p* \< 0.05 was considered statistically significant. STATISTICA version 9.1 (StatSoft Inc., Tulsa, USA) was used for the statistical analysis.

Results {#Sec3}
=======

Expression of p21^WAF1^ (Fig. [1a--d](#Fig1){ref-type="fig"}) was found in the nuclei of 60.4% (166/275) of all cases, in 54.1% (72/133) of stage B2 cancers, and in 66.2% (94/142) of stage C tumors. Of all the parameters examined, only Astler--Coller stage was associated with p21^WAF1^ expression (Table [1](#Tab1){ref-type="table"}). Fig. 1Expression of p21^WAF1^in representative cores of CRC. **a**, **b** High expression of p21^WAF1^ in the nuclei of tumor cells. **c**, **d** Low expression of p21^WAF1^ in the nuclei of cancer cells. **b**, **d** Fragments of the cores from a and c, respectively, at high magnification

**Group B2** No association was found between p21^WAF1^ expression and DFS or OS in the whole B2 group, neither in univariate or multivariate analysis (data not shown). However, 83 patients in this group were treated with 5FU-based adjuvant chemotherapy, and 50 patients were not. Further analysis of the association of p21^WAF1^ expression with DFS and OS in these subgroups showed that expression of p21^WAF1^ was associated with DFS (*p* = 0.025) and OS (*p* = 0.0079) only in the subgroup of stage B2 patients that were treated with adjuvant chemotherapy (Fig. [2a](#Fig2){ref-type="fig"}). Moreover, p21^WAF1^ expression remained in this subgroup as the only independent prognostic parameter in the multivariate analysis in relation to DFS and OS (*p* = 0.035 and *p* = 0.02, respectively; Table [2](#Tab2){ref-type="table"}). In the stage B2 subgroup of patients not treated with chemotherapy, none of the parameters studied were associated with DFS or OS (data not shown). Fig. 2DFS (*black curves*) and OS (*red curves*) of stage B2 patients treated with adjuvant chemotherapy categorized according to the p21 expression (*n* = 83) (**a**) and of stage B2 patients with p21-positive tumors categorized according to adjuvant chemotherapy (*n* = 72) (**b**). DFS (*black curves*) and OS (*red curves*) of stage C patients (*n* = 120) (**c**) and of stage B2 + C patients (*n* = 203) (**d**) treated with adjuvant chemotherapy categorized according to p21 expressionTable 2Multivariate analysis of disease-free and overall survival of stage B2 and C patients treated with adjuvant chemotherapyCategoryB2 (*n* = 83)C (*n* = 120)Disease-free survivalOverall survivalDisease-free survivalOverall survivalHazard ratio (95% Cl)*p*Hazard ratio (95% Cl)*p*Hazard ratio (95% Cl)*p*Hazard ratio (95% Cl)*p*Sex0.97 (0.37--2.53)0.950.99 (0.24--4.04)0.991.21 (0.71--2.08)0.491.50 (0.73--3.05)0.27Age0.99 (0.95--1.03)0.631.00 (0.94--1.07)0.991.02 (0.99--1.05)0.121.02 (0.99--1.05)0.29Grade0.56 (0.20--1.57)0.270.39 (0.08--1.86)0.241.93 (1.12--3.33)*0.018*2.87 (1.37--6.01)*0.005*Tumor site0.99 (0.29--3.47)0.102.55 (0.64--10.15)0.190.57 (0.27--1.17)0.130.35 (0.10--1.15)0.08P21^WAF1^0.36 (0.14--0.93)*0.035*0.16 (0.03--0.76)*0.02*0.60 (0.35--1.04)0.070.48 (0.24--0.93)*0.03*In the subgroup of 72 stage B2 patients with p21^WAF1^ expression, adjuvant chemotherapy was associated with better DFS (85% 5-year survival versus 65% without chemotherapy, *p* = 0.03; Fig. [2b](#Fig2){ref-type="fig"}) and OS (96% 5-year survival versus 82% without chemotherapy, *p* = 0.014; Fig. [2b](#Fig2){ref-type="fig"}). In the subgroup of 61 stage B2 patients with negative p21^WAF1^ expression, a trend for the association of chemotherapy with worse survival (both DFS and OS) was observed, but the differences were not statistically significant (data not shown).

**Group C** The expression of p21^WAF1^ in tumors of patients treated with adjuvant chemotherapy was associated with DFS in a univariate analysis (HR = 0.58, 95% CI = 0.34--0.99, *p* = 0.047) and was on the verge of statistical significance in the multivariate analysis (*p* = 0.07) (Table [2](#Tab2){ref-type="table"}). In terms of OS, there was a statistically significant association with p21^WAF1^ expression in both the univariate (HR = 0.41, 95% CI = 0.21--0.80, *p* = 0.008) and multivariate (*p* = 0.03) (Table [2](#Tab2){ref-type="table"}) analyses. Kaplan--Meier survival curves of patients with p21^WAF1^ expression in the nuclei of cancer cells indicate better DFS (*p* = 0.055) and significantly better OS (72% versus 45% 5-year survival of patients with negative p21^WAF1^ expression, *p* = 0.0079; Fig. [2c](#Fig2){ref-type="fig"}).

**Stage B2 + C patients treated with adjuvant chemotherapy** Expression of p21^WAF1^ was associated with DFS and OS (*p* = 0.03 and *p* = 0.002, respectively) in a univariate analysis. The Astler--Coller stage and p21^WAF1^ expression were found to be independent prognostic factors for DFS and OS (Table [3](#Tab3){ref-type="table"}). In multivariate analysis, there was no statistically significant association between site of CRC (neither rectum versus colon nor proximal versus distal as defined by the splenic flexure) and DFS (*p* = 0.77, *p* = 0.28, respectively) or OS (*p* = 0.77, *p* = 0.28, respectively). Kaplan--Meier survival curves showed significantly better DFS and OS of patients with tumors showing p21^WAF1^ expression as compared to those negative for p21^WAF1^ (*p* = 0.03 and *p* = 0.0018, respectively; Fig. [2d](#Fig2){ref-type="fig"}). Table 3Multivariate analysis of disease-free and overall survival of patients treated with adjuvant chemotherapy (group B2 + C, *n* = 203)CategoryDisease-free survivalOverall survivalHazard ratio (95% Cl)*p*Hazard ratio (95% Cl)*p*Sex1.20 (0.75--1.90)0.441.42 (0.77--2.65)0.27Age1.01 (0.99--1.03)0.321.01 (0.98--1.04)0.58Astler--Coller3.16 (1.86--5.36)*\<0.0001*3.60 (1.77--7.33)*0.0004*Grade1.48 (0.94--2.32)0.091.95 (1.07--3.56)*0.03*Tumor site0.64 (0.34--1.20)0.170.62 (0.26--1.49)0.28P21^WAF1^0.52 (0.33--0.83)*0.0062*0.36 (0.20--0.66)*0.0009*

Discussion {#Sec4}
==========

We found p21^WAF1^ nuclear expression in 60.4% CRCs which is comparable to the literature data (16--87%) \[[@CR11], [@CR13]--[@CR15], [@CR28], [@CR29]\]. The majority of reports (but not all) concerning the prognostic role of p21^WAF1^ expression in CRCs indicate better OS and/or DFS for patients with tumors showing p21^WAF1^ expression (Table [4](#Tab4){ref-type="table"}). In some of these reports, p21^WAF1^ expression was an independent prognostic factor for OS and/or DFS (Table [4](#Tab4){ref-type="table"}). However, in those reports, patients with various stages of the disease who were subjected to different treatment protocols (surgery alone, surgery and adjuvant chemotherapy, radiochemotherapy) were often grouped together for the analysis, or no information on the mode of therapy is given. Thus, it is difficult to infer whether stage II patients with p21^WAF1^-positive tumors may receive any benefit from adjuvant chemotherapy. Table 4Major reports on p21^WAF1^ expression and survival of patients with CRCsSourceStudy groupStage of CRC and type of treatmentResultsCheng J.D., et al. \[[@CR10]\]*n* = 39Metastatic CRC 5FU CHTH5FU responders had greater p21 expressionRopponen K.M, et al. \[[@CR11]\]*n* = 1620--D incl. 62--B majority: surgery only; 22--CHTHBetter OS and RFS for patients with p21+ tumors; p21: independent prognostic parameter for OS and RFS (MA)Viale G., et al. \[[@CR12]\]*n* = 191I--IV CHTH?↓p21 → poor OS and DFS (UA)Bukholm I.K., et al. \[[@CR13]\]*n* = 61B--D CHTH?Low p21 → increased risk of metastases and deathZirbes T.K., et al. \[[@CR14]\]*n* = 294I--IV incl. 90--II. surgery CHTH?Better OS for patients with p21+ tumors; p21 independent prognostic parameter (MA)Holland T.A., et al. \[[@CR15]\]*n* = 126A--D RCHTH?Better OS for patients with high p21 expressionPasz-Walczak G., et al. \[[@CR16]\]*n* = 122I--IV CHTH?Better OS for patients with p21+ tumors (UA)Watanabe T., et al. \[[@CR20]\]*n* = 460II (B)--105 III (C)--355, 5FU CHTHNo association of p21 expression with survival in all and in stage B tumorsHoss A., et al. \[[@CR21]\]*n* = 100T2--3, N0 rectum, surgery onlyNo association of p21 expression with survivalSchwandner O., et al. \[[@CR17]\]*n* = 160I--III rectum, surgery, *n* = 69 surgery + CHTH + RT, *n* = 91Better RFS but not OS for patients with p21+ tumors; p21 independent prognostic parameter for RFS but not OS (MA)Rau B., et al. \[[@CR22]\]*n* = 66T3--4, N0--2, M0--1 rectum, RCHTHNo prognostic significance of pretreatment p21 expression. Post-treatment increase of p21: shorter DFSPrall F., et al. \[[@CR18]\]*n* = 184I--IV incl. 55-III, III: *n* = 32 -5FU, *n* = 23-5FU + RTBetter OS for patients with p21 + tumors (MA)Mitomi H., et al. \[[@CR19]\]*n* = 211B--D incl. 83-B CHTH for C--DBetter OS for patients with high p21 expression; p21 independent prognostic parameter (MA)Ioachim E., et al. \[[@CR23]\]*n* = 97Dukes B, C, surgery, CHTH?No association of p21 expression with OS and DFSNoske A., et al. \[[@CR24]\]*n* = 116II--III RCHTHBetter RFS and OS for patients with p21- tumors↓ down regulation, *UA* univariate analysis, *MA* multivariate analysis, *OS* overall survival, *DFS* disease-free survival, *RFS* relapse-free survival, *RT* radiotherapy, *CHTH* chemotherapy, *RCHTH* radiochemotherapy, *?* not known

The benefit of adjuvant 5FU-based chemotherapy has been firmly established for patients with stage III CRC. However, in the stage B2 group, it is not known whether the survival benefit from chemotherapy is sufficient to outweigh the toxicity and cost of the treatment \[[@CR2]\]. Only one study \[[@CR20]\] has addressed the issue of the influence of 5FU-based adjuvant chemotherapy on the survival of patients with stage B2 CRC in relation to p21^WAF1^ expression. In that study, pretreatment levels of p21^WAF1^ were not related to survival of patients with stage II (and III) CRC treated with adjuvant chemotherapy. However, increased levels of p21^WAF1^ were associated with the sensitivity of metastatic CRC to 5FU-based chemotherapy \[[@CR10]\].

Our results indicate for the first time that p21^WAF1^ expression in CRC tumor cells is an independent factor that is associated with favorable DFS and OS in patients with stage B2 tumors treated with 5FU-based adjuvant chemotherapy. Striking survival benefits were seen for stage B2 patients who received adjuvant chemotherapy compared with those who did not. Conversely, chemotherapy did not significantly influence DFS or OS of stage B2 patients with p21^WAF1^-negative tumors. Rather, a statistically non-significant trend towards worse survival was observed for stage B2 patients with p21^WAF1^-negative tumors treated with chemotherapy. The differences between our results and those of Watanabe et al. \[[@CR20]\] may be attributed to the different scoring systems and different cutoff points used for the interpretation of immunohistochemical staining, as well as to differences in immunohistochemical methods. The major advantage of tissue microarrays is that tens of cases can be processed in identical laboratory conditions which greatly improves the reproducibility of the immunohistochemical method. Prall et al. \[[@CR18]\] used tissue microarrays (*n* = 184) and found better OS for combined group of stage I--IV patients with p21^WAF1^-positive tumors. Our results (from the whole group) are well in accord with this report and give further support for the association of p21^WAF1^ expression and longer survival of patients with stage C/III CRCs treated with adjuvant 5FU-based chemotherapy as has been reported previously (Table [4](#Tab4){ref-type="table"}). One limitation of TMA technology is that "punched" cores from donor tissues may not always be representative of the entire tumor. In this report, we applied one core from carefully identified, histologically relatively homogenous area with the highest mitotic activity in the outer invasive zone of each CRC. Using this approach, we found 60.4% of p21^WAF1^-positive CRCs which is within the range reported in the literature. Hoos et al. \[[@CR30]\] reported that correlations between phenotypes and clinical outcome were not significantly different between full sections and triplicate 0.6-mm core tissue microarrays. However, on the other hand, they were not significantly different when only one 0.6-mm core tissue microarray was used \[[@CR31]\]. The authors of the latter report conclude that tissue microarray "with a single core per specimen ensures full biological representativeness to identify the associations between biomarkers and clinico-pathological parameters, with no significant associated sampling bias." So, careful sampling of the representative region of the tumor is regarded as the key step in the construction of tissue microarrays.

TS, the target enzyme for 5FU, is essential for DNA synthesis \[[@CR32]\], and it may function as an oncogene \[[@CR33]\]. Inhibition of TS induces apoptosis and cytotoxicity in human colorectal cancer cells \[[@CR7]\]. The importance of p21^WAF1^ in the response of CRC to chemotherapeutic agents is supported by in vitro studies \[[@CR7]--[@CR9]\]. It has been reported that p21^WAF1^ (a CDK inhibitor) regulates thymineless stress-induced cytotoxicity of human colon carcinoma cell lines \[[@CR7]\]. Also, TS expression is mediated through the inhibition of CDK: TS expression was upregulated by the knockout of the p21^WAF1^ gene in a CRC cell line \[[@CR8]\]. In addition, reduction of TS expression results in enhancement of the sensitivity to 5FU in human CRC cell lines \[[@CR8]\]. Our results are in line with other reports that show that p21^WAF1^ is a critical mediator of the cytotoxic action of TS inhibitors in cultured human colorectal cancer cells \[[@CR7]\] and that CDK inhibitor enhances the sensitivity to 5FU in colorectal cancer cell lines \[[@CR8]\]. In fact, p21^WAF1^ is required for maximal cytotoxicity induced by thymineless stress in colorectal cancer cells in culture \[[@CR7]\]. Poor survival of patients with p21^WAF1^-negative tumors treated with adjuvant 5FU-based chemotherapy may perhaps be attributed to inherent resistance to 5FU. It has been shown that development of resistance to 5FU by colon cancer cell lines is associated with downregulation of the *CDKN1A* gene, along with other genes engaged in DNA damage response/repair pathway \[[@CR34]\].

In summary, we found that p21^WAF1^ expression in CRC tumor cells identifies a subgroup of Astler--Coller stage B patients who would benefit significantly from 5FU-based chemotherapy and may therefore allow for better selection of patients for adjuvant chemotherapy. We believe that, in order to maximize the benefit of 5FU-based adjuvant therapy and to spare patients from unnecessary toxicity, stage B2 patients should be stratified according to p21^WAF1^ status. However, because this is a retrospective study, our results should be confirmed by further prospective randomized investigations.
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